Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 7/20 | 0.73 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.73 |
| ▸ | MET | P08581 | 5/20 | 0.53 |
| ▸ | RET | P07949 | 2/20 | 0.53 |
| ▸ | FLT3 | P36888 | 2/20 | 0.53 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.53 |
| ▸ | PLK4 | O00444 | 1/20 | 0.53 |
| ▸ | GAK | O14976 | 1/20 | 0.53 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.53 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.53 |
| ▸ | ERN1 | O75460 | 1/20 | 0.53 |
| ▸ | STK10 | O94804 | 1/20 | 0.53 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.53 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.53 |
| ▸ | ABL1 | P00519 | 1/20 | 0.53 |
| ▸ | EGFR | P00533 | 1/20 | 0.53 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.53 |
| ▸ | LCK | P06239 | 1/20 | 0.53 |
| ▸ | FYN | P06241 | 1/20 | 0.53 |
| ▸ | CSF1R | P07333 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29902450 | 0.92 | KDR (0.70) | KDRPDGFRBMETRETFLT3 | |
| SCHEMBL28516088 | 0.92 | KDR (0.68) | KDRPDGFRBMETRETFLT3 | |
| SCHEMBL28571054 | 0.92 | KDR (0.70) | KDRPDGFRBMETRETFLT3 | |
| SCHEMBL28519841 | 0.92 | KDR (0.70) | KDRPDGFRBMETRETFLT3 | |
| SCHEMBL28572514 | 0.92 | KDR (0.70) | KDRPDGFRBMETRETFLT3 | |
| Hydrochloric Acid SCHEMBL29902483 | 0.91 | KDR (0.69) | KDRPDGFRBMETRETFLT3 | |
| Hydrochloric Acid SCHEMBL28573091 | 0.91 | KDR (0.69) | KDRPDGFRBMETRETFLT3 | |
| Hydrochloric Acid SCHEMBL28569161 | 0.91 | KDR (0.69) | KDRPDGFRBMETRETFLT3 | |
| Hydrochloric Acid SCHEMBL28569162 | 0.91 | KDR (0.69) | KDRPDGFRBMETRETFLT3 | |
| SCHEMBL28528916 | 0.90 | KDR (0.66) | KDRPDGFRBMETRETFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2125776-A1 | SPIRO SUBSTITUTED COMPOUNDS AS ANGIOGENESIS INHIBITORS | Advenchen Laboratories, LLC (US) | 2009-12-02 | — | — | EP | claimed |
| WO-2008112407-A1 | SPIRO SUBSTITUTED COMPOUNDS AS ANGIOGENESIS INHIBITORS | ADVENCHEN LABORATORIES, LLC (US) | 2008-09-18 | — | — | WO | claimed |
| US-20080227811-A1 | Spiro Substituted Compounds As Angiogenesis Inhibitors | ADVENCHEN LABORATORIES, LLC | 2008-09-18 | — | — | US | claimed |
| EP-3513809-B9 | MEDICINAL COMPOSITION COMPRISING TIVOZANIB | KYOWA KIRIN CO LTD (JP) | 2022-07-13 | — | — | EP | disclosed |
| EP-3400942-B1 | USE OF QUINOLINE DERIVATIVES FOR TREATING OESOPHAGEAL CANCER AND TREATMENT METHOD, PHARMACEUTICAL COMPOSITION AND KIT THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2022-04-13 | — | — | EP | disclosed |
| EP-3973964-A1 | QUINOLINE DERIVATIVE USED FOR COMBINATION TREATMENT OF SMALL CELL LUNG CANCER | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2022-03-30 | — | — | EP | disclosed |
| EP-3967310-A1 | QUINOLINE DERIVATIVE USED FOR SOFT TISSUE SARCOMA COMBINATION THERAPY | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-03-16 | — | — | EP | disclosed |
| EP-3513809-B1 | MEDICINAL COMPOSITION COMPRISING TIVOZANIB | KYOWA KIRIN CO LTD (JP) | 2022-03-02 | — | — | EP | disclosed |
| EP-3854396-A1 | QUINOLINE DERIVATIVE USED FOR TREATING SMALL CELL LUNG CANCER | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2021-07-28 | — | — | EP | disclosed |
| EP-3766496-A1 | QUINOLINE DERIVATIVE FOR TREATMENT OF NASOPHARYNGEAL CARCINOMA | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2021-01-20 | — | — | EP | disclosed |
| WO-2020233723-A1 | QUINOLINE DERIVATIVES FOR TREATMENT OF HEAD AND NECK CANCER | 正大天晴药业集团股份有限公司 (CN) | 2020-11-26 | — | — | WO | disclosed |
| WO-2020057536-A1 | QUINOLINE DERIVATIVE FOR TREATING BRAIN TUMOR | 正大天晴药业集团股份有限公司 | 2020-03-26 | — | — | WO | disclosed |
| EP-3231797-B1 | QUINOLINE DERIVATIVE AGAINST NON-SMALL CELL LUNG CANCER | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2020-02-26 | — | — | EP | disclosed |
| WO-2019174590-A1 | QUINOLINE DERIVATIVE FOR TREATMENT OF TRIPLE-NEGATIVE BREAST CANCER | 正大天晴药业集团股份有限公司 | 2019-09-19 | — | — | WO | disclosed |
| EP-2125776-B1 | SPIRO SUBSTITUTED COMPOUNDS AS ANGIOGENESIS INHIBITORS | ADVENCHEN LABORATORIES LLC (US) | 2017-07-05 | — | — | EP | disclosed |
| EP-3153170-A1 | METHODS AND USES OF QUINOLINE DERIVATIVES IN THE TREATMENT OF SOFT TISSUE SARCOMAS AND PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF SAME | Chia Tai Tianqing Pharmaceutical Group Co.,Ltd (CN) | 2017-04-12 | — | — | EP | disclosed |
| EP-3153169-A1 | METHOD FOR TREATING TUMOUR, PHARMACEUTICAL COMPOSITION AND MEDICINE BOX KIT | Chia Tai Tianqing Pharmaceutical Group Co.,Ltd (CN) | 2017-04-12 | — | — | EP | disclosed |
| EP-2125776-A1 | SPIRO SUBSTITUTED COMPOUNDS AS ANGIOGENESIS INHIBITORS | Advenchen Laboratories, LLC (US) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008112407-A1 | SPIRO SUBSTITUTED COMPOUNDS AS ANGIOGENESIS INHIBITORS | ADVENCHEN LABORATORIES, LLC (US) | 2008-09-18 | — | — | WO | disclosed |
| US-20080227811-A1 | Spiro Substituted Compounds As Angiogenesis Inhibitors | ADVENCHEN LABORATORIES, LLC | 2008-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227811-A1 | Spiro Substituted Compounds As Angiogenesis Inhibitors | TEK, KDR, TIE1 | KDR 2/4885PDGFRB 6/4885MET 176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.